Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC 50 of 120 ng/ml. 125I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4% ID/g at 2 h post-injection. Both naive and 200 μCi 188Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.
|Original language||English (US)|
|Number of pages||9|
|State||Published - Feb 1 2014|
ASJC Scopus subject areas
- Pharmaceutical Science